Shuttle Pharmaceuticals shares are trading higher after the company announced the issuance of U.S. Patent No. 12,077,515, titled "Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease."
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharmaceuticals shares rose following the issuance of a new U.S. patent for their selective histone deacetylase inhibitors, which are used in treating human diseases.
September 05, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shuttle Pharmaceuticals' stock is trading higher due to the issuance of a new U.S. patent for their selective histone deacetylase inhibitors, which could enhance their treatment offerings.
The issuance of a new patent is a positive development for Shuttle Pharmaceuticals as it strengthens their intellectual property portfolio and could lead to new treatment options, driving investor interest and potentially increasing stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100